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Propranolol sensitizes prostate 
cancer cells to glucose metabolism 
inhibition and prevents cancer 
progression
Laura Brohée1, Olivier Peulen  2, Betty Nusgens1, Vincent Castronovo2, Marc Thiry3, Alain C. 
Colige1 & Christophe F. Deroanne1
Propranolol, a widely used non-selective beta-adrenergic receptor blocker, was recently shown to 
display anticancer properties. Its potential to synergize with certain drugs has been also outlined. 
However, it is necessary to take into account all the properties of propranolol to select a drug that could 
be efficiently combined with. Propranolol was reported to block the late phase of autophagy. Hence, 
we hypothesized that in condition enhancing autophagy flux, cancer cells should be especially sensitive 
to propranolol. 2DG, a glycolysis inhibitor, is an anti-tumor agent having limited effect in monotherapy 
notably due to induction of pro-survival autophagy. Here, we report that treatment of cancer cells 
with propranolol in combination with the glycolysis inhibitor 2DG induced a massive accumulation of 
autophagosome due to autophagy blockade. The propranolol +2DG treatment efficiently prevents 
prostate cancer cell proliferation, induces cell apoptosis, alters mitochondrial morphology, inhibits 
mitochondrial bioenergetics and aggravates ER stress in vitro and also suppresses tumor growth in vivo. 
Our study underlines for the first time the interest to take advantage of the ability of propranolol to 
inhibit autophagy to design new anti-cancer therapies.
Cancer cells differ from normal cells by various hallmarks1 such as metabolism reprogramming that furnishes 
the energy and the (macro-)molecules allowing their rapid proliferation. Various metabolic pathways, including 
glycolysis and the biosynthesis of nucleic acid, protein or lipid, are altered in tumor cells and represent promising 
targets for anti-cancer therapies2. In a previous study, we highlighted the role of lipin-1, an enzyme participat-
ing to lipid anabolism, in regulating cancer cell phenotype and metabolism3. Lipins can regulate various cellu-
lar processes including gene expression, proliferation, migration and autophagy4. Through their phosphatidate 
phosphatase (PAP) activity, generating diacylglycerol (DAG) from phosphatidic acid (PA), they contribute to the 
fusion of autophagosomes with lysosomes and to autophagy clearance5. Autophagy is a ubiquitous catabolic pro-
cess essential for cell survival under stress conditions6,7. Its role in cancer is complex and depends on biological 
factors, such as the tumor type or the driving oncogene8. It is also part of the pro-survival response of cancer cells 
to anti-cancer treatment and its inhibition was reported to enhance cancer cell death9,10.
Propranolol is a β-adrenergic receptor blocker notably used for the treatment of hypertension, myocardial 
infarction, anxiety and tremor11. Numerous studies have also demonstrated its efficacy for the treatment of infan-
tile haemangiomas in human12,13. Propranolol is also an inhibitor of the PAP activity of lipins, which probably 
explains why it inhibits autophagy flux3,14. Furthermore, retrospective analyses reported a decreased risk of head 
and neck, stomach, colon and prostate cancers in patients receiving propranolol15.
2-deoxy-d-glucose (2DG), a glucose analog, is blocking the first critical step of glycolysis, therefore mimick-
ing glucose deprivation, and leading to metabolic stress16,17. It interferes also with N-glycosylation of proteins 
thus preventing their normal folding and inducing endoplasmic reticulum (ER) stress18,19. Although 2DG is an 
anti-tumor agent, its effects in monotherapy are quite limited and combination with other drugs is required to 
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achieve an efficient anticancer treatment20. Molecules aiming at inhibiting the 2DG-induced autophagy are par-
ticularly harmful to cancer cells21,22.
In view of their individual specific effects on cancer cells, we hypothesized that the combination of propranolol 
and 2DG might exert a synergistic toxic effect on cancer cells. Prostate cancer cells were used as an informative 
model in this study since this type of cancer is associated with an upregulation of lipogenic enzymes23, including 
lipin-13, and with an elevated basal autophagy that protects prostate cancer cells from cytotoxic treatments7. 
Here, we report that combined treatment is effective on preventing prostate cancer cell proliferation, inducing cell 
apoptosis, altering mitochondrial morphology, inhibiting mitochondrial bioenergetics, aggravating ER stress in 
vitro and, most importantly, in suppressing tumor growth in vivo.
Results
Culture in low glucose or glycolysis inhibition sensitizes cancer cells to propranolol. PC3 
Prostate cancer cells have a basal autophagy flux essential for their tumorigenic phenotype24. When treated with 
propranolol, PC3 cells accumulate high amounts of the autophagy markers p62 and LC3-II (Fig. 1a). The use 
of cells expressing a fluorescent recombinant tagged LC3 (LC3-eGFP-mCherry) demonstrated that propranolol 
blocks autophagy clearance which results in a high percentage of early autophagosomes (Fig. 1b,c). LC3-II accu-
mulates also in low glucose condition and this accumulation increases further upon addition of E64d, a cathepsin 
inhibitor (Fig. 2a,b). This suggested an increased autophagy flux which was further confirmed by recombinant 
tagged LC3 experiments demonstrating the lack of blockade of autophagy clearance (Supplementary Fig. S1). 
Since autophagy is an important mechanism allowing cells to survive to various stresses, including starvation, we 
hypothesized that the combination of low glucose and propranolol could be harmful for cells due to the blockade 
of autophagy. While treatment with low glucose or propranolol alone already inhibited the proliferation of PC3 
cells, the combination of both completely blocked proliferation and even led to cell death since the cell number 
after 3 days of treatment, as evaluated by DNA content measurements, was lower than the originally seeded cell 
number (Fig. 2c). This was confirmed by direct evaluation of cell death. At 7 mM glucose propranolol increased 
cell death very slightly (+2.6%). By sharp contrast the effect of propranolol was markedly increased (+15.3%) 
at low glucose concentration (Fig. 2d). Glucose deprivation can be mimicked in vitro by culturing cells with 
2DG, a glycolysis inhibitor. Accumulation of LC3-II was observed in the presence of 2DG and this accumulation 
was increased in the presence of E64d, suggesting an increased autophagy flux as observed with low glucose 
(Fig. 3a,b). Furthermore, the use of cells expressing a recombinant tagged LC3 demonstrated the lack of blockade 
of autophagy clearance in 2DG treated cells since no accumulation of early autophagosome was noticed (Fig. 3c 
and Supplementary Fig. S2). Based on these data, we hypothesized that propranolol might sensitize cancer cells to 
2DG. While the proliferation of PC3 cells was significantly decreased in presence of propranolol (100 µM) or 2DG 
(1, 2 or 10 mM) alone (Fig. 4a), the combined treatment completely blocked the proliferation of PC3 cells (Fig. 4a) 
at 1 and 2 mM 2DG (p values < 0.001) and even led to a decreased cell number at 10 mM 2DG (p value < 0.01) 
after 3 days of culture as already observed for cultures at low glucose (Fig. 2c). These effects are clearly visible by 
phase contrast microscopy already at 48 h (Fig. 4b). While the cell shape and number were affected by propran-
olol or 2DG used alone, the combined treatment was much more potent. Cells were rounded, barely attached 
and their number was reduced as compared to respectively propranolol or 2DG used alone. Quantification of 
cell death by FACS confirmed the visual observations (Fig. 4c). The 2DG + P combination induces a 4.9 fold 
increase of cell death in the aggressive prostate cancer cells PC3. To broaden the significance of our results, we 
tested the effect of 2DG and propranolol alone or in combination on cells originating from another type of can-
cer. We observed that this effect was not limited to PC3 and prostate cancer cells since it induces also cell death 
in breast cancer cells (x4.5 and x8.3, as compared to controls, for MDAMB231 and 4T1 respectively) (Fig. 4d). 
Interestingly, the combination of both drugs had a less pronounced effect (about 2 fold increase) on two low- and 
non-tumorigenic prostatic cell lines (LnCaP and PNT1A) (Fig. 4c).
The combination of 2DG and propranolol enhances autophagy blockade and exacerbates ER 
stress. Since we hypothesized that the combination of 2DG and propranolol could impair autophagy, we eval-
uated the expression levels of LC3-II and p62. As compared to controls, propranolol or 2DG treatments led to the 
accumulation of LC3-II (x5.7 and x2.7, respectively) and p62 (x2.6 and 3.0, respectively) already after 24 hours. 
This effect was enhanced when the two drugs were added together (x6.5 for LC3II and x6.3 for p62) (Fig. 5a) and 
was further increased after 48 h (x15.4 for LC3II and of x11.9 for p62) (Fig. 5b). Similar results were also obtained 
with MDAMB231 cells (Supplementary Fig. S3). These data suggested a dramatic accumulation of autophago-
somes due to a lack of maturation. This was confirmed by electron microscopy analyses which reveal a massive 
accumulation of vesicles formed by a double membrane containing cytoplasmic material (compare Fig. 5c,f–h). 
These analyses revealed also that PC3 cells exposed to the combined treatment are characterized by a denser ER 
lumen (see arrows Fig. 6a,b) and vesicle accumulation on the Golgi (Supplementary Fig. S4). In order to inves-
tigate the ER stress response, we measured the expression level of the pro-survival component of this system, 
glucose-related protein of molecular mass 78 (GRP78), and of its pro-apoptotic counterpart, C/EBP homologous 
protein (CHOP). Propranolol treatment did not induce GRP78 or CHOP expression while a significant increase 
was observed upon 2DG treatment (x15.6 for CHOP, x11.4 for GRP78), but without significantly changing the 
ratio between the two proteins. By contrast, the double treatment further enhanced CHOP expression (x35.7) but 
decreases the expression of GRP78 (x 8.3) as compared to 2DG treatment alone (x11.4) which strongly affects the 
CHOP/GRP78 ratio and suggest a dramatic aggravation of ER stress (Fig. 6c,d). A similar regulation of CHOP 
and GRP78 was also observed with MDAMB231 cells (Fig. 6e,f).
Combining 2DG to propranolol leads to a strong inhibition of mitochondrial bioenerget-
ics. Although accumulation of p62 can be a marker of mitophagy, we did not observe any mitochondria inside 
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Figure 1. Propranolol blocks autophagy in PC3 cells and induces a massive accumulation of autophagosomes. 
PC3 cells were untreated (C) or treated with 100 µM propranolol (P) for 24 h or 48 h. (a) As compared to 
control (C), P treatment induces an increase of LC3-II and p62 in PC3 cells both at 24 and 48 h. Western 
blot quantifications were normalized on Erk1/2, used as control for protein loading. Results are expressed 
as fold increase compared to the control condition. (b,c) Autophagy flux was investigated by the transient 
overexpression of a LC3-eGFP-mCherry construct combined, or not, with P treatment (100 µM) for 24 
or 48 hours. (b) Graphical representation of the percentages of early/late autophagosomes, after 48 h of 
treatment, as determined in at least 24 cells per condition (mean ± s.d.). Representative fluorescent microscopy 
photographs of each condition are shown in (c) (scale bars = 10 µm).
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Figure 2. Low glucose condition increases autophagy and enhances sensitivity to propranolol in PC3 cells. PC3 
cells were cultured in medium containing 7% dialyzed FBS and 1 mM or 7 mM glucose for the indicated times. 
(a) Autophagy was investigated by LC3-II/LC3-I and p62 western blotting followed by a normalization on 
Erk1/2 to control protein loading. Under low glucose PC3 cells have an increased autophagy flux. (b) Cells were 
challenged or not with 10 μg/ml of E64d, a cathepsin inhibitor, for 72 h. Treatment with E64d further enhances 
the low glucose-dependent accumulation of LC3-II and p62. (c,d) Cells were treated or not with 100 μM 
propranolol (P) for the indicated amount of time. (c) The proliferation of treated PC3 cells was measured as 
described in the “Materials and Methods”. P strongly inhibits PC3 cells proliferation in low glucose condition. 
(d) The percentage of death of PC3 cells was quantified by FACS after culture during 72 h. Propranolol induces 
cell death more efficiently in low than high glucose conditions. FACS analysis was performed after labeling PC3 
cells with FITC-annexin V and propidium iodide. 10 000 events were collected for each experiment.
www.nature.com/scientificreports/
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Figure 3. Glycolysis blockade by 2DG induced an increase of autophagy flux in PC3 cells. PC3 cells were 
treated or not with 10 mM 2DG for 24 or 48 hours. (a) 2DG treatment induces an increase of autophagy as 
showed by LC3-II and p62 accumulation both at 24 and 48 hours. (b) Cells were treated or not with 2DG and 
with (+E64d), or without, 10 μg/ml of the cathepsin inhibitor E64d for 48 h. Blocking the lysosomal proteases 
with E64d further enhances the 2DG-dependent accumulation of LC3-II and p62. Erk1/2 was used as protein 
loading control. (c) Autophagy flux was investigated by the transient overexpression of a LC3-eGFP-mCherry 
construct combined, or not, with 10 mM 2DG treatment for 24 or 48 h. Representative fluorescent microscopy 
photographs are shown (scale bars = 10 µm). No accumulation of autophagosomes is observed in 2DG 
condition.
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double membrane vesicles in PC3 cells with the double treatment (Fig. 5f,h). However, mitochondria exhibited 
a condensed configuration which was never observed in control cells (see arrows and compare Supplementary 
Fig. S5a,b). Furthermore, the network of mitochondria, stained in living cells with TMRE, was profoundly altered 
Figure 4. Propranolol and 2DG synergize in inducing arrest of proliferation and cell death of cancer cells. 
PC3 cells were treated with increasing concentrations of 2DG (1, 2 and 10 mM), propranolol (P) (100 µM) or 
both. (a) The proliferation of cells was measured by DNA content quantification as indicated in “Materials and 
Methods”. 2DG and P synergize to arrest PC3 cells. (b) Phase contrast microscopy photographs show the status 
of PC3 cells after 48 h of treatments (scale bar = 250 µm). (c,d) Cell death was measured by FACS analysis after 
labeling cells with FITC-annexin-V and propidium iodide. 10 000 events were collected for each experiment. 
(c) PC3, LnCaP and PNT1A were treated with 2DG (10 mM), propranolol (P) (100 µM) or both for 48 h. (d) 
MDAMB231 and 4T1 cells were treated with 2DG (10 mM and 2 mM respectively), propranolol (P) (100 µM 
and 50 µM respectively) or both for 48 h. Propranolol and 2DG synergize in inducing cancer cell death.
www.nature.com/scientificreports/
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Figure 5. Propranolol and 2DG combined treatment results in massive accumulation of autophagosomes. 
PC3 cells were treated with 2DG (10 mM), propranolol (P) (100 µM), or both together, and were collected at 
the indicated times. (a,b) The levels of LC3-II and p62 were investigated by immune-blotting after 24 h or 48 h 
of treatment and normalized to Erk1/2 used as protein loading control. LC3-II and p62 further accumulate 
when the two drugs were added simultaneously, highlighting a dramatic accumulation of autophagosomes. 
Results are expressed as fold increase as compared to the control condition. (c–h) PC3 cells were collected 
after 24 h of treatments and prepared for electron microscopy analysis as detailed in “Materials and Methods”. 
Representative images of a cell in control condition (c,g), after exposure to P (d), to 2DG (e) or to the combined 
treatment (f,h) show an accumulation of autophagosomes in 2DG + P condition (see white arrows, c to f scale 
bar = 1 µm, (g,h) scale bars = 5 µm).
www.nature.com/scientificreports/
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in PC3 cells exposed to both drugs (Supplementary Fig. S5c,d). The percentage of cells presenting morphological 
modifications of their mitochondrial network increases progressively with time and reached a maximum after 
24 h of treatment (Supplementary Fig. S6). Interestingly, PNT1A control cells were less sensitive than PC3 cells 
(Supplemental Fig. S7). Modifications of the mitochondrial network suggested an altered mitochondrial function. 
Figure 6. 2DG + P induces ER stress in PC3 and MDAMB231 cells. PC3 cells and MDAMB231 were left 
untreated (C) or treated with 2DG (10 mM), propranolol (P) (100 µM) or both together (P+2DG) for the 
indicated times. (a,b) Electron microscopy comparison of control PC3 vs PC3 treated with 2DG + P (scale 
bars = 500 nm). The arrows pinpoint the ER structures. In 2DG+P condition ER appears condensed. PC3 
(c,d) or MDAMB231 (e,f) cells were investigated for ER stress markers CHOP (c,e) and GRP78 (d,f). Signal 
quantifications are normalized to Erk1/2 as a control of protein loading. CHOP is drastically increased in cells 
treated with 2DG+P.
www.nature.com/scientificreports/
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To assess the effect of treatment on mitochondrial respiration, real-time measurements of the oxygen consump-
tion rate were performed. Propranolol or 2DG treatment alone did not significantly affect mitochondrial activity 
in PC3 cells (Fig. 7a,c–h). By contrast, the presence of both 2DG and propranolol causes a significant reduction 
of the basal and maximal respirations as compared to control cultures and to cultures in presence of 2DG or pro-
pranolol alone (Fig. 7i,j). In parallel, the ATP production-related respiration was also significantly diminished by 
the combined treatment (Fig. 7l) while the spare capacity – defined as the difference between maximal and basal 
respiration – was not significantly decreased (p = 0.054) (Fig. 7k). No modification in non-mitochondrial respi-
ration and in proton leak was observed between 2DG alone and 2DG+ propranolol conditions (Fig. 7m,n). These 
defects of mitochondrial function were associated with a decreased glycolysis rate as revealed by measurements of 
the extracellular acidification rate (ECAR) in the various tested conditions (Fig. 7o). These results demonstrated 
the potent anti-mitochondrial properties of the 2DG and propranolol combination.
Combined treatment with 2DG and propranolol reduces in vivo tumor growth. To extend our in 
vitro findings, we examined the effect of the 2DG+ propranolol treatment on in vivo tumor growth in mice. Drug 
dosage was based on literature data and did not induce toxicity. PC3 cells were injected in the flank of NOD SCID 
mice. After 10 days, mice were randomly separated in four groups and treated daily for 16 days by intraperitoneal 
injection of vehicle alone (PBS), propranolol (10 mg/kg) alone, 2DG (500 mg/kg) alone or 2DG+propranolol. 
Only the combined treatment induced a significant decrease of tumor weight and volume at the end of the exper-
iment (Fig. 8) as compared to the control condition (PBS), confirming the interest of using both drugs together.
Discussion
Retrospective studies on patients treated with propranolol reported a protective effect against various types of 
cancers, including prostate cancer15, and have led to investigation of its anti-tumoral properties25–27. Recently, 
it has been reported that propranolol can be efficiently combined with metabolic inhibitors like rapamycin or 
metformin to target cancer cells3,28. Beside its β-adrenergic receptor blocker activity, propranolol can strongly 
inhibit the PAP activity of lipins29–31. Lipin-1, a member of the lipin family, was reported to be overexpressed in 
various cancer types and its silencing or inhibition prevents cancer cells proliferation in vitro and tumor growth 
in vivo, highlighting the interest of its targeting in anti-cancer therapy3,32,33. In a recent study, we observed that 
phenotypical modifications induced in cancer cells by lipin-1 silencing can be recapitulated by propranolol treat-
ment3. Moreover, it is also likely through its ability to inhibit the PAP activity of lipins that propranolol blocks 
autophagy5, a cell survival mechanism induced to resist to stressors like starvation. Hence, we hypothesized that 
propranolol-treated cancer cells should be sensitized to metabolic stress inducing survival autophagy. This was 
investigated in vitro in low glucose conditions or in presence of the metabolic inhibitor 2DG21. As expected, the 
association of 2DG and propranolol was especially harmful for cancer cells in blocking proliferation and inducing 
cell death. The blockage by propranolol of the autophagy flux induced by 2DG resulted in a strong accumulation 
of LC3-II and p62 and in a massive accumulation of autophagic vesicles. Pharmacological aggravation of endo-
plasmic reticulum (ER)-stress is a principle exploited for cancer therapeutic applications which can be induced 
by autophagy inhibition34. The aggravation of ER-stress observed upon 2DG+ propranolol treatment is likely due 
to the autophagy blockade mediated by propranolol which would promote cell death by overloading the tumor 
cells’ adaptation capacity. This is illustrated by the shift of the balance between the antiapoptotic GRP78 and the 
proapoptotic CHOP towards CHOP which induce cell death. The combined treatment also induced a dramatic 
disorganization of the mitochondrial network suggesting an imbalance between the fusion and fission states of 
mitochondria. This equilibrium can be affected by an altered balance between lipid species. Phosphatidic acid 
and diacylglycerol were reported to regulate the mitochondrial fusion/fission balance35,36 and propranolol as well 
as 2DG can affect the relative concentrations of these two lipid species37. As an additional feature, Ca2+ can be 
released from ER stressed by the presence of both 2DG and propranolol and would contribute to mitochondrial 
fragmentation via the Miro GTPase38. By transmission electron microscopy it was also observed that mitochon-
dria in propranolol+2DG-treated cells displayed a condensed morphology. All these morphological alterations 
were reminiscent of mitochondrial dysfunction. This was confirmed by real-time measurements of the oxygen 
consumption rate demonstrating a reduction of mitochondrial respiration. In our conditions, insufficient respira-
tion cannot be compensated by increased glycolysis suggesting that lack of intracellular energy could also contrib-
ute to the dramatic phenotype observed with the combined treatment. Finally, the significant inhibition of in vivo 
tumor growth in mice treated with 2DG+ propranolol observed here as well as the good tolerance of 2DG and 
propranolol in clinical trials20,39 suggest the possibility to use the combination 2DG+ propranolol in anti-cancer 
therapies. Our study highlights for the first time the interest to take advantage of the ability of propranolol to 
inhibit autophagy in cancer. Propranolol appears as a potential alternative to other autophagy modulators which 
are relatively toxic in noncancerous tissues40. More widely, this property of propranolol should be taken into 
account for the treatment of other pathologies characterized by an excessive autophagy like neurodegenerative 
diseases.
Materials and Methods
Cell lines and reagents. Hoechst H33258 was purchased from Calbiochem (Merck, Overijse, Belgium). 
Sodium pyruvate, sodium cacodylate, glutamine, glucose, carbonyl cyanide 4-(trifluoromethoxy)-phenylhydra-
zone (FCCP), oligomycin, rotenone, antimycin A, 2-deoxy-D-glucose (D6134), (±)-propranolol hydrochloride 
(P0884) were from Sigma (Darmstadt, Germany). Glutaraldehyde was from Bioconnect (The Netherlands). 
Human prostate adenocarcinoma cells (PC3) were grown in Ham’s F-12K medium (Invitrogen, Merelbeke, 
Belgium) complemented by 7% Foetal Bovine Serum (FBS) (Lonza, Verviers, Belgium) or cultured in DMEM 
(Lonza) supplemented with 7% dialyzed FBS and different concentrations of glucose. Human breast adeno-
carcinoma cells (MDAMB231) and mouse mammary adenocarcinoma cells (4T1) were cultured in DMEM 
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Figure 7. 2DG combined with propranolol decreases mitochondrial respiration. PC3 cells were treated with 
2DG (2DG) (10 mM), propranolol (P) (100 µM) or both for 24 h. PC3 cells were analyzed for mitochondrial 
bioenergetics using the Agilent Seahorse XF technology. (a,b) Measurement of basal level of oxygen 
consumption rate (OCR) was followed by sequential injections of oligomycin, FCCP, and rotenone/antimycin 
A. (a) The OCR in control (CTRL), P and 2DG conditions were not significantly different. (b) Comparison of 
2DG and 2DG+P condition shows a decrease of OCR in the double treated condition. (c–n) Quantification 
graph of OCR parameter: (c,i) basal and (d,j) maximal respirations. Both are reduced in the 2DG+P condition 
only. (e,k) Quantification of spare capacity and (f,l) ATP production-related OCR. OCR related to ATP 
production is significantly decreased in PC3 cells treated with 2DG+P, while spare capacity is not significantly 
different (p = 0.054). (g,m) Quantification of non-mitochondrial OCR and (h,l) proton leak. These two 
parameters are not altered by the double treatment. (o) Extracellular acidification rate (ECAR) measured 
with the Agilent Seahorse XF technology. Measurement of basal level of ECAR was followed by sequential 
injections of oligomycin, FCCP, and rotenone/antimycin A. The ECAR was not significantly modified in the P 
condition as compared to the CTRL condition while the ECAR is significantly decreased in the 2DG alone and 
2DG+propranolol conditions.
www.nature.com/scientificreports/
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supplemented with 7% FBS. Human immortalized prostatic cells (PNT1A) and prostate carcinoma cells (LnCaP) 
were grown in RPMI 1640 (Lonza) supplemented with 7% FBS. All media were supplemented with penicil-
line-streptomycine (100 units/ml each) and Fungizone (250 ng/ml). PC3 cells were authenticated as reported in3 
(DSMZ, Braunschweig, Germany).
Western blotting. Cells were solubilised in SDS-PAGE lysis buffer and equal amount of protein were loaded 
and separated by polyacrylamide gel electrophoresis. After separation, proteins were transferred to a PVDF 
membrane (NEN Life Science Products), blocked in 3% dry milk in PBS-Tween 20 (0.05%) and probed with 
the following primary antibodies for 3 hours: rabbit antibodies against lipin-1 (#sc98450), p62/sequestosome 1 
(#sc28359) and GRP78 (#sc13968) were from Santa-Cruz Biotechnology (Bioconnect). Rabbit antibody against 
Erk1/2 (#M5670) was from Sigma, mouse antibody against LC3 (#0260-100) and mouse antibody against CHOP 
(#2895) were respectively from Nanotools (Merck) and from Cell Signaling (Bioke, Leiden, Netherlands). After 
the primary antibody exposition, membranes were washed three times with PBS-Tween and incubated 1 h with 
the diluted secondary antibodies: rabbit anti-mouse IgG (P0260) or swine anti-rabbit IgG (P0217), both conju-
gated to horseradish peroxidase and purchased from DAKO (Heverlee, Belgium). The blots were then revealed 
by chemoluminescence using home-made reagents and images were acquired and quantified with ImageQuant™ 
Las4000© (GE Healthcare Life Sciences). As a loading control, the membranes were re-probed with an antibody 
against Erk1/2. Erk1/2 was chosen because its expression level is not regulated by cell morphology alterations 
like cytoskeletal proteins41 and unlike GAPDH, another commonly used control, it is not directly involved in cell 
metabolism.
Proliferation assay. Cell proliferation was determined by DNA content measurements42, as previously 
described3,43. Briefly, cells were seeded in 24-well plates and processed at different time points. The cells were 
rinsed three times with saline and lyzed in PBS by sonication. In a 96-well plate 100 μl of lysate was mixed 1/1 with 
a hoechst solution (2 µg/ml hoechst, 4 M NaCl, 0.02 M NaH2PO4, pH 7.4). Fluorescence was measured in a spec-
trofluorometer SpectraMax i3 (Molecular Devices, Sunnyvale, California, USA) (excitation wavelength 355 nm, 
emission wavelength 460 nm). A DNA standard curve was included in every 96-well plate.
Mitochondrial network visualization. Mitochondria visualization in living cells was performed using 
TMRE (tetramethyl rhodamine ethyl ester) (#87917 Sigma) labelling. TMRE is a cationic dye that is rapidly accu-
mulated by mitochondria. 105 cells/well were seeded in 8-wells micro-Slides (#80826, IBIDI, Munich, Germany). 
At different time points cells were loaded for 20 min at 37 °C with 1 nM TMRE in culture medium and analyzed 
Figure 8. Propranolol and 2DG together inhibit tumor growth in vivo. 2 × 106 PC3 cells were injected 
subcutaneously in each flank of nude mice (n = 20 mice). The tumors were allowed to grow for 11 days and then 
the animals were separated in four groups (n = 10 tumors in each condition). Each group received a specific 
treatment: Control (PBS), propranolol (P), 2DG (2DG) and 2DG+P (2DG+P) as described in the “Materials 
and Methods”. After 16 days, mice were sacrificed. The tumors were macroscopically observed (a), measured (b) 
and weighed (c). The double treatment induced a significant reduction of tumor size and weight. Bar = 5 mm.
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by epifluorescence microscopy. The acquired images were analyzed with ImageJ software. The network status of 
the cell was visually characterized as normal if filamentous mitochondria were the only observed mitochondria, 
intermediate if filamentous mitochondria and puncta mitochondria coexisted and altered if only puncta were 
present.
Autophagy analyses.  Autophag y f lux was  invest igated using the  reporter  plasmid 
pBABE-puro-mCherry-EGFP-LC3B (Addgene) as reported previously44. Briefly, PC3 cells were transfected for 
16 hours with 1 μg of plasmid per well in 6-well plates. Then, the cells were trypsinized and seeded in 8-wells 
micro-Slides (IBIDI). After attachment the cells were treated with propranolol, 2DG or cultured in low glucose 
condition for the indicated times. The images were acquired by epifluorescence microscopy after 24 and 48 hours 
of treatment and the ratio between early (red and green) and late autophagosomes (red only) was quantified with 
the ImageJ software. The analyses were performed on stacked images of several focal planes.
Cell survival and apoptosis. Cell survival and apoptosis were evaluated by FACS analysis following man-
ufacturer instructions of the Annexin V-FITC Apoptosis Detection kit (Sigma). Flow cytometry was performed 
on a FACS-Canto II double LASER flow cytometer (UV, 488 nm, 633 nm) (BD Biosciences, Franklin Lakes, New 
Jersey) and data were analyzed using FACSDiva Software (BD Biosciences). The cells negative for both Annexin-V 
and PI are considered as “live cells” while cells positive for either one or both markers are considered “dead cells”.
Extracellular Flux Analysis for determination of respiratory capacities. 104 cells/well were seeded 
in Seahorse XFp mini-plates (Agilent, Santa Clara, California) and allowed to attach overnight. After 24 hours 
drug treatment, cells were kept in unbuffered serum-free XF assay medium (Agilent) supplemented with pyru-
vate (1 mM), glutamine (2 mM), glucose (10 mM), pH7.4 at 37 °C and ambient CO2 for one hour before the 
assay. During the assay, cells were successively stressed with oligomycin (1 µM), FCCP (0,5 µM) and a rotenone/
antimycine A (0.5 µM each) mix. FCCP concentration was chosen according to45. The readout of the assay was 
the oxygen consumption rate (pmoles/min). Results were normalized according to the cell number evaluated by 
Hoechst (2 µg/ml) incorporation after cold methanol/acetone (4:1) fixation.
Transmission electron microscopy (TEM) analysis. At the end of the 24 hour drugs treatments, 
cells were fixed for 1 h in a 0.1 M sodium cacodylate buffer (pH 7.4) containing 2.5% glutaraldehyde (v/v) and 
post-fixed for 30 min with 2% (w/v) osmium tetroxide in the same buffer. Samples were then dehydrated at room 
temperature through an increasing ethanol series (70%, 96% and 100%) and embedded in Epon for 48 h at 60 °C. 
Ultrathin sections (70 nm thick) were obtained by using an ultramicrotome (Reichert Ultracut E Leica, Wetzlar, 
Germany), equipped with a diamond knife (Diatome, Hatfield, Pennsylvania). The sections were mounted on 
copper grids coated with collodion and contrasted with uranyl acetate and lead citrate for 15 min each. The 
ultrathin sections were observed under a JEM-1400 transmission electron microscope (Jeol, Croissy Sur Seine, 
France) at 80 kV and micrographs were taken with an 11 MegaPixel bottom-mounted TEM camera system 
(Quemesa, Olympus, Münster, Germany).
Animal experiments. Experimental protocol was approved by the ethical committee of the University of 
Liège (approval document n°1701) according to the European Communities Council Directive. NOD SCID 
male mice were bred and housed in pathogen-free condition. All procedures were performed in accordance 
with the Federation of European Laboratory Animal Science Associations (FELASA) guidelines. A volume of 
200 μl of serum-free medium containing 2 × 106 PC3 cells was inoculated into both flanks of mice (6–8 weeks 
old, n = 20). After 10 days, tumors had reached an average volume of 50 mm3. Mice were then treated daily with 
intra-peritoneal injections (100 µL) of PBS (control group), of propranolol (10 mg/kg), of 2DG (500 mg/kg), or of 
both drugs. After 16 days of treatment mice were sacrificed by cervical dislocation and decapitated. After resec-
tion tumor weight were measured and tumor sizes were assessed by measuring the length and width of tumors, 
and the volume was determined by using the following formula: (length) × (width)2 × 0.4. The data are presented 
as means ± s.d.
Statistical analyses. Statistical analyses were performed using Mann-Whiney U test or ANOVA test 
followed by Tukey-Kramer post-test (GraphPad Prism software, GraphPad Sofware, La Jolla, CA, USA) with 
p ≤ 0.05 considered as significant. In the figures data are expressed as mean ± standard deviations of biological 
triplicates, annotations are as follow: not significant (ns), p < 0.05 (*)p < 0.01 (**)p < 0.001 (***).
Data availability Statement. All data generated or analysed during this study are included in this pub-
lished article and its Supplementary Information files.
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